You are here: Industry Insights > Venclexta

News List

FDA grants BTD for Venclexta in combination with azacitidine to treat patients with myelodysplastic syndromes expresspharma
July 22, 2021
Every year, approximately 10,000 people are diagnosed with myelodysplastic syndromes (MDS) in the US, and there remains a high unmet need for new treatment options.
Chemotherapy-free combination shows potential in lymphocytic leukaemia trial europeanpharmaceuticalreview
June 09, 2021
Imbruvica® (ibrutinib) plus Venclexta®/Venclyxto® (venetoclax) resulted in 95 percent of chronic lymphocytic leukaemia patients surviving without disease progression for two years.
VENCLEXTA Receives FDA Approval for AML americanpharmaceuticalreview
October 22, 2020
AbbVie announced the U.S. Food and Drug Administration (FDA) has provided full approval to VENCLEXTA® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia ..
AbbVie’s Venclexta granted full US approval in AML pharmatimes
October 22, 2020
The US Food and Drug Administration (FDA) has fully approved AbbVie’s Venclexta in acute myeloid leukaemia (AML).
Genentech announces full FDA approval for Venclexta combinations for acute myeloid leukaemia expresspharma
October 19, 2020
Genentech, a member of the Roche Group, announced that the US Food and Drug Administration (FDA) has granted full approval of Venclexta (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment ...
AbbVie announces positive topline results from phase 3 trial of VENCLEXTA, Azacitidine combo in AML pharmaceutical-business-review
March 27, 2020
AbbVie announced the VIALE-A (M15-656) trial of VENCLEXTA (venetoclax) in combination with azacitidine versus azacitidine in combination ...
Positive results announced for acute myeloid leukaemia treatment trial europeanpharmaceuticalreview
March 27, 2020
Positive topline results have been announced from a Phase II trial of VENCLEXTA® (venetoclax) in combination with azacitidine in patients with acute myeloid leukaemia (AML).
AbbVie Announces Positive Results from VENCLEXTA, Azacitidine Combination for AML americanpharmaceuticalreview
March 26, 2020
AbbVie announced the VIALE-A (M15-656) trial of VENCLEXTA® (venetoclax) in combination with azacitidine versus azacitidine in combination ...
Venclexta/Venclyxto combo extends myeloid leukaemia survival pharmatimes
March 25, 2020
Roche has announced that its Phase III VIALE-A study, evaluating Venclexta/Venclyxto (venetoclax) in combination with azacitidine for acute myeloid leukaemia (AML), has met its dual primary endpoints.
VENCLEXTA, Low-Dose Cytarabine Combination Study for AML Does Not Meet Primary Endpoint americanpharmaceuticalreview
March 04, 2020
AbbVie announced the VIALE-C (M16-043) trial of venetoclax (VENCLEXTA®) in combination with low-dose cytarabine (LDAC) versus LDAC in combination with placebo did not meet its primary endpoint of ...

Previous page 1 2 Next page